FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ZNF212-PDE3B

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ZNF212-PDE3B
FusionPDB ID: 101629
FusionGDB2.0 ID: 101629
HgeneTgene
Gene symbol

ZNF212

PDE3B

Gene ID

7988

5140

Gene namezinc finger protein 212phosphodiesterase 3B
SynonymsC2H2-150|ZNF182|ZNFC150HcGIP1|cGIPDE1
Cytomap

7q36.1

11p15.2

Type of geneprotein-codingprotein-coding
Descriptionzinc finger protein 212Zinc finger protein C2H2-150cGMP-inhibited 3',5'-cyclic phosphodiesterase BCGI-PDE BCGIP1cyclic GMP-inhibited phosphodiesterase Bcyclic nucleotide phosphodiesterasephosphodiesterase 3B, cGMP-inhibited
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000335870, ENST00000534317, 
ENST00000282096, ENST00000455098, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 3=277 X 7 X 4=196
# samples 37
** MAII scorelog2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0		log2(7/196*10)=-1.48542682717024
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ZNF212 [Title/Abstract] AND PDE3B [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ZNF212 [Title/Abstract] AND PDE3B [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PDE3B(14856641)-ZNF212(148947772), # samples:2
ZNF212(148947898)-PDE3B(14839729), # samples:2
Anticipated loss of major functional domain due to fusion event.ZNF212-PDE3B seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ZNF212-PDE3B seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ZNF212-PDE3B seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ZNF212-PDE3B seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PDE3B-ZNF212 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
PDE3B-ZNF212 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
PDE3B-ZNF212 seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:14856641/chr11:148947772)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ZNF212 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PDE3B (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000335870ZNF212chr7148947898+ENST00000282096PDE3Bchr1114839729+36306691282485785
ENST00000335870ZNF212chr7148947898+ENST00000455098PDE3Bchr1114839729+27206691282485785

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000335870ENST00000282096ZNF212chr7148947898+PDE3Bchr1114839729+0.004119430.9958806
ENST00000335870ENST00000455098ZNF212chr7148947898+PDE3Bchr1114839729+0.0102521230.9897479

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ZNF212-PDE3B

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ZNF212chr7148947898PDE3Bchr1114839729669181VMESNYETLVSLSVLSSLSPVNSSNH

Top

Potential FusionNeoAntigen Information of ZNF212-PDE3B in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ZNF212-PDE3B_148947898_14839729.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B45:01YETLVSLSV0.9980.9222514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B50:02YETLVSLSV0.99570.7163514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B15:17VSLSVLSSL0.99320.8624918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:38SVLSSLSPV0.99230.77991221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:35SVLSSLSPV0.99160.72771221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:21SVLSSLSPV0.99120.80171221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B15:16VSLSVLSSL0.98930.5784918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:20SVLSSLSPV0.98850.70031221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:13SVLSSLSPV0.98820.76531221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:11SVLSSLSPV0.98820.7131221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:29SVLSSLSPV0.9880.69111221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:30SVLSSLSPV0.98720.69621221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:24SVLSSLSPV0.98720.69621221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:67SVLSSLSPV0.98720.69621221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:27SVLSSLSPV0.98560.69441221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:16SVLSSLSPV0.98520.60481221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B57:03VSLSVLSSL0.95630.9584918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B18:01YETLVSLSV0.93980.9513514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B47:01YETLVSLSV0.87270.7333514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B50:01YETLVSLSV0.85090.7652514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B41:01YETLVSLSV0.83310.9564514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B52:01VSLSVLSSL0.80360.7061918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B39:13YETLVSLSV0.53940.9118514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B52:01YETLVSLSV0.36340.9224514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B40:06YETLVSLSV0.99940.5857514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:07VSLSVLSSL0.99930.984918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C15:06VSLSVLSSL0.99910.9119918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:08VSLSVLSSL0.99910.9346918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C15:04VSLSVLSSL0.9990.8592918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:19VSLSVLSSL0.9990.9917918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C04:06VSLSVLSSL0.99460.9071918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C12:04VSLSVLSSL0.99070.9974918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C12:12VSLSVLSSL0.990.9672918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C06:03VSLSVLSSL0.98990.9972918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:01SVLSSLSPV0.98720.69621221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C08:13VSLSVLSSL0.98720.9691918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C08:04VSLSVLSSL0.98720.9691918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B44:10YETLVSLSV0.95440.538514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B40:03YETLVSLSV0.94630.5312514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C02:06VSLSVLSSL0.79510.9745918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B39:08YETLVSLSV0.59570.8809514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B51:07YETLVSLSV0.25840.8167514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:03VSLSVLSSL0.99930.9938918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:04VSLSVLSSL0.99930.9938918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C15:09VSLSVLSSL0.9990.8592918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:05VSLSVLSSL0.99890.9529918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C15:05VSLSVLSSL0.99890.9048918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C15:02VSLSVLSSL0.99890.8642918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:17VSLSVLSSL0.99880.9856918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B40:04YETLVSLSV0.9960.7251514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:03SVLSSLSPV0.99290.761221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A25:01ETLVSLSVL0.99190.912615
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A68:02ETLVSLSVL0.99180.7039615
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:14SVLSSLSPV0.99140.70411221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A02:06SVLSSLSPV0.99120.80171221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C03:06VSLSVLSSL0.98810.9934918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A69:01SVLSSLSPV0.98460.8861221
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-A69:01ETLVSLSVL0.97820.7661615
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C16:02VSLSVLSSL0.96530.9922918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B18:05YETLVSLSV0.93980.9513514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B18:08YETLVSLSV0.9390.9352514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B18:06YETLVSLSV0.93670.9551514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B18:03YETLVSLSV0.92620.9471514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B50:05YETLVSLSV0.85090.7652514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B50:04YETLVSLSV0.85090.7652514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B41:03YETLVSLSV0.82040.6369514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B57:02VSLSVLSSL0.82030.9185918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-C17:01VSLSVLSSL0.7630.9259918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B35:13VSLSVLSSL0.73430.8851918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B18:11YETLVSLSV0.62820.9399514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B39:31YETLVSLSV0.53410.9515514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B39:02YETLVSLSV0.47390.9232514
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B07:13VSLSVLSSL0.12410.8586918
ZNF212-PDE3Bchr7148947898chr1114839729669HLA-B40:04YETLVSLSVL0.99540.6881515

Top

Potential FusionNeoAntigen Information of ZNF212-PDE3B in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ZNF212-PDE3B_148947898_14839729.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-0111ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-0129ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1002LSVLSSLSPVNSSNH1126
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1222ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1527ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1534ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1601ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1602ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1602MESNYETLVSLSVLS116
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1603ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1604ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1605ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1605MESNYETLVSLSVLS116
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1607ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1607MESNYETLVSLSVLS116
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1608ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1609ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1610ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1610MESNYETLVSLSVLS116
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1611ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1611MESNYETLVSLSVLS116
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1612ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1612MESNYETLVSLSVLS116
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1614ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1614MESNYETLVSLSVLS116
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1616ESNYETLVSLSVLSS217
ZNF212-PDE3Bchr7148947898chr1114839729669DRB1-1616MESNYETLVSLSVLS116

Top

Fusion breakpoint peptide structures of ZNF212-PDE3B

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2177ETLVSLSVLSSLSPZNF212PDE3Bchr7148947898chr1114839729669

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ZNF212-PDE3B

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2177ETLVSLSVLSSLSP-6.33173-6.44513
HLA-B14:023BVN2177ETLVSLSVLSSLSP-1.81046-2.84576
HLA-B52:013W392177ETLVSLSVLSSLSP-5.92784-6.04124
HLA-B52:013W392177ETLVSLSVLSSLSP-4.3074-5.3427
HLA-A24:025HGA2177ETLVSLSVLSSLSP-6.68795-7.72325
HLA-A24:025HGA2177ETLVSLSVLSSLSP-5.73606-5.84946
HLA-B44:053DX82177ETLVSLSVLSSLSP-6.99493-8.03023
HLA-B44:053DX82177ETLVSLSVLSSLSP-6.82556-6.93896
HLA-A02:016TDR2177ETLVSLSVLSSLSP-4.47214-5.50744

Top

Vaccine Design for the FusionNeoAntigens of ZNF212-PDE3B

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ZNF212-PDE3Bchr7148947898chr11148397291221SVLSSLSPVTGAGTGTTTTGTCCAGTCTGAGTCCTG
ZNF212-PDE3Bchr7148947898chr1114839729514YETLVSLSVACTATGAGACACTGGTCTCTCTGAGTG
ZNF212-PDE3Bchr7148947898chr1114839729515YETLVSLSVLACTATGAGACACTGGTCTCTCTGAGTGTTT
ZNF212-PDE3Bchr7148947898chr1114839729615ETLVSLSVLATGAGACACTGGTCTCTCTGAGTGTTT
ZNF212-PDE3Bchr7148947898chr1114839729918VSLSVLSSLTGGTCTCTCTGAGTGTTTTGTCCAGTC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ZNF212-PDE3Bchr7148947898chr1114839729116MESNYETLVSLSVLSTGATGGAGAGTAACTATGAGACACTGGTCTCTCTGAGTGTTTTGT
ZNF212-PDE3Bchr7148947898chr11148397291126LSVLSSLSPVNSSNHCTCTGAGTGTTTTGTCCAGTCTGAGTCCTGTGAATTCTTCCAACC
ZNF212-PDE3Bchr7148947898chr1114839729217ESNYETLVSLSVLSSTGGAGAGTAACTATGAGACACTGGTCTCTCTGAGTGTTTTGTCCA

Top

Information of the samples that have these potential fusion neoantigens of ZNF212-PDE3B

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SKCMZNF212-PDE3Bchr7148947898ENST00000335870chr1114839729ENST00000282096TCGA-WE-A8ZM-06A

Top

Potential target of CAR-T therapy development for ZNF212-PDE3B

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ZNF212-PDE3B

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ZNF212-PDE3B

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource